# Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia

> **NCT06608342** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia ALL

## Interventions

- **BIOLOGICAL:** Autologous hematopoietic stem cell transplantation combined with CD19-CART

## Key facts

- **NCT ID:** NCT06608342
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-25
- **Primary completion:** 2026-05-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06608342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06608342, "Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06608342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*